

PD Dr Barbara Mayer

Work address Ludwig-Maximilians-University Munich
Department of General, Visceral and Transplant Surgery
V I02-307
Marchioninstr. 15
81377 München
D-Germany

Contact phone 0049-89-4400 76438

E-mail address Barbara.Mayer@med.uni-muenchen.de

Experience of work

- Since 2006 Co-founder and managing director of SpheroTec GmbH
- Since 2001 Principal Investigator “Cancer metastasis”, Department of General, Visceral and Transplant Surgery, University of Munich, Germany
- 1998-2001 Post-Doc, Sunnybrook Health Sciences Centre, Toronto, Canada

Education

- 2006 Associated Professor in Experimental Oncology, University of Munich, Germany
- 1998 PhD in biology, University of Munich, Germany

Most relevant scientific publications (technology related)

1. **Mayer B**, Klement G, Kaneko M, Man S, Jothy S, Rak J, Kerbel RS. Multicellular gastric cancer spheroids recapitulate growth pattern and differentiation phenotype of human gastric carcinomas. *Gastroenterology* 2001; 121:839-52.
2. Bachmeier BE, Vene R, Iancu CM, Pfeffer U, **Mayer B**, Noonan D, Albini A, Jochum M, Nerlich A. Transcriptional control of cell density dependent regulation of matrix metalloproteinase and TIMP expression in breast cancer cell lines. *Thromb Haemost* 2005, 93: 761-9.
3. Gaedtke L, Thoenes L, Culmsee C, **Mayer B**, Wagner E. Proteomic analysis reveals differences in protein expression in spheroid versus monolayer cultures of low-passage colon carcinoma cells. *J Proteome Res.* 2007, 6: 4111-8.
4. Witthauer J, Schlereth B, Brischwein K, Winter H, Funke I, Jauch K-W, Baeuerle P, **Mayer B**. Lysis of cancer cells by autologous T cells in breast cancer pleural effusates treated with anti-EpCAM BiTE antibody MT110. *Breast Cancer Res Treat* 2009; 117:471-81.
5. Eichner J, Heubach Y, Ruff M, Kohlhof H, Strobl S, **Mayer B**, Pawlak M, Templin MF, Zell A. RPPApipe: a pipeline for the analysis of reverse-phase protein array data.

Biosystems 2014; 122:19-24.

6. Hoffmann O, Ilmberger C, Magosch S, Joka M, Jauch K-W, **Mayer B**. Impact of the spheroid model complexity on drug response, *J Biotechnol* 2015, 205: 14-23.
7. Halfter K, Ditsch N, Kolberg H-C, Fischer H, Edler von Koch F, Bauerfeind I, von Minckwitz G, Funke I, Crispin A, **Mayer B**. Prospective cohort study using the breast cancer spheroid model as a predictor for response to neoadjuvant therapy-the SpheroNEO study. *BMC Cancer* 2015, 15:519-529.
8. Halfter K, Hoffmann O, Ditsch N, Paepke S, Grab D, Bauerfeind I, **Mayer B**. Testing chemotherapy efficacy in HER2 negative breast cancer using patient-derived spheroids. *J Transl Med* 2016, 14: 112.
9. Geiger P, **Mayer B**, Wiest I, Schulze S, Jeschke U, Weissenbacher T. Binding of galectin-1 to breast cancer cells MCF-7 induces apoptosis and inhibition of proliferation in vitro in a 2D and 3D-cell culture model. *BMC Cancer* 2016, 16: 870.
10. Halfter K, **Mayer B**. Bringing 3D tumor models to the clinic. *Biotechnol. J* 2017, 12:1.
11. **Mayer B**, Karakhanova S, Bauer N, Liu L, Zhu Y, Philippov P, Werner J, Bazhin A. Anticancer effect of regorafenib on pancreatic carcinoma cells in vitro, ex vivo and in vivo. *Naunyn-Schmiedeberg's Archives of Pharmacology*, 2017, 390 (11):1125-1134
12. Miksch R, Hao J, Dötzer K, Schlüter F, Weniger M, Yin S, Ormanns S, D'Haese J, Guba M, Werner J, **Mayer B**, Bazhin A, Schoenberg M. Development of a reliable and accurate algorithm to quantify the tumor stroma (QTS) across tumor entities. *Oncotarget* 2017, 8 (79): 114935-114944.
13. Schoenberg MB, Hao J, Bucher JN, Miksch RC, Anger HJW, **Mayer B**, Mayerle J, Neumann J, Guba MO, Werner J, Bazhin AV. Perivascular tumor-infiltrating leukocyte scoring for prognosis of resected hepatocellular carcinoma patients. *Cancers*, 2018, 10 (10):389-402.
14. Miksch RC, Schoenberg MB, Weniger M, Bösch F, Ormanns S, **Mayer B**, Werner J, Bazhin AV, D'Haese JG. Prognostic impact of tumor-infiltrating lymphocytes and neutrophils on survival of patients with upfront resection of pancreatic cancer. *Cancers*, 2019, 11(1):1-19.
15. Doetzer K, Schlueter F, Schoenberg M, Bazhin A, Koch F, Schnelzer A, Anthuber S, Grab D, Czogalla B, Burges A, Werner J, **Mayer B**. Immune heterogeneity between primary tumors and corresponding metastatic lesions predicts platinum response in primary ovarian cancer. *Cancers*, 2019, 11(9): 1250-1264.